Citadel Advisors
CDIO icon

Citadel Advisors’s Cardio Diagnostics CDIO Stock Holding History

Citadel Advisors’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.8K Buy
+19,071
New +$36.1K ﹤0.01% 13204
2026
Q1 		– Sell
-10,858
Closed -$29.4K – 13081
2025
Q4 		$29.4K Sell
10,858
-8,662
-44% -$31.5K ﹤0.01% 12230
2025
Q3 		$78.7K Buy
+19,520
New +$77.1K ﹤0.01% 11984

Other funds holding CDIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's CDIO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cardio Diagnostics (CDIO) in Q2 2026: 19,071 shares worth $41.8K. The stake represents ﹤0.01% of the portfolio and ranks #13204 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CDIO as recently as Q4 2025.

Citadel Advisors first reported a position in CDIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $78.7K in Q3 2025. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Citadel Advisors held 19,071 shares of Cardio Diagnostics worth $41.8K as of Q2 2026.
  • Cardio Diagnostics was a new Citadel Advisors position in Q2 2026.
  • Cardio Diagnostics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13204 holding.
  • Citadel Advisors first reported a position in Cardio Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • Citadel Advisors's Cardio Diagnostics position peaked at $78.7K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.